Literature DB >> 10631454

Evolving approaches to cancer drug discovery and development at the National Cancer Institute, USA.

E A Sausville1, E Feigal.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10631454     DOI： 10.1023/a:1008333901925

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  7 in total

1.  Balancing safety, effectiveness, and public desire: the FDA and cancer.

Authors:  Rena Conti
Journal:  Issue Brief (Commonw Fund)       Date:  2003-04

Review 2.  Small-Molecule Screens: A Gateway to Cancer Therapeutic Agents with Case Studies of Food and Drug Administration-Approved Drugs.

Authors:  Nathan P Coussens; John C Braisted; Tyler Peryea; G Sitta Sittampalam; Anton Simeonov; Matthew D Hall
Journal:  Pharmacol Rev       Date:  2017-10       Impact factor: 25.468

Review 3.  Murine models to evaluate novel and conventional therapeutic strategies for cancer.

Authors:  James E Talmadge; Rakesh K Singh; Isaiah J Fidler; Avraham Raz
Journal:  Am J Pathol       Date:  2007-03       Impact factor: 4.307

Review 4.  Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents.

Authors:  Sreenath V Sharma; Daniel A Haber; Jeff Settleman
Journal:  Nat Rev Cancer       Date:  2010-03-19       Impact factor: 60.716

5.  ROADMAPS: An Online Database of Response Data, Dosing Regimens, and Toxicities of Approved Oncology Drugs as Single Agents to Guide Preclinical In Vivo Studies.

Authors:  Melinda G Hollingshead; Nathaniel Greenberg; Michelle Gottholm-Ahalt; Richard Camalier; Barry C Johnson; Jerry M Collins; James H Doroshow
Journal:  Cancer Res       Date:  2022-06-15       Impact factor: 13.312

Review 6.  Global gene expression profiling in the study of multiple myeloma.

Authors:  John D Shaughnessy
Journal:  Int J Hematol       Date:  2003-04       Impact factor: 2.490

7.  Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials.

Authors:  J I Johnson; S Decker; D Zaharevitz; L V Rubinstein; J M Venditti; S Schepartz; S Kalyandrug; M Christian; S Arbuck; M Hollingshead; E A Sausville
Journal:  Br J Cancer       Date:  2001-05-18       Impact factor: 7.640
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.